Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
35.78
+0.83 (2.37%)
At close: Jan 6, 2026, 4:00 PM EST
35.80
+0.02 (0.06%)
After-hours: Jan 6, 2026, 7:49 PM EST
Corcept Therapeutics Employees
Corcept Therapeutics had 500 employees as of December 31, 2024. The number of employees increased by 148 or 42.05% compared to the previous year.
Employees
500
Change (1Y)
148
Growth (1Y)
42.05%
Revenue / Employee
$1,482,344
Profits / Employee
$209,312
Market Cap
3.76B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 500 | 148 | 42.05% |
| Dec 31, 2023 | 352 | 53 | 17.73% |
| Dec 31, 2022 | 299 | 61 | 25.63% |
| Dec 31, 2021 | 238 | 2 | 0.85% |
| Dec 31, 2020 | 236 | 30 | 14.56% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CORT News
- 13 hours ago - Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman - PRNewsWire
- 2 days ago - Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug - Seeking Alpha
- 6 days ago - Why Corcept Therapeutics stock crashed today and what comes next? - Invezz
- 6 days ago - Corcept Therapeutics Shares Drop 50% After FDA Rejects Drug - Barrons
- 6 days ago - US FDA declines to approve Corcept's drug for rare hormonal disorder - Reuters
- 6 days ago - Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism - Business Wire
- 15 days ago - Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely? - Benzinga
- 2 months ago - Corcept Therapeutics Incorporated (CORT) Q3 2025 Earnings Call Transcript - Seeking Alpha